Commit Biologics announces €5.5m seed financing extension investment by Korys to further develop its Bispecific Complement Engaging platform

Commit Biologics California

Additional funding from new investor Korys, joining existing syndicate members Novo Holdings and Bioqube Ventures, brings total seed financing to €21.5mFunds will be used to further develop Commit's BiCE platform and move towards drug candidate (DC) selectionEva Van Overmeire, Senior Investment Manager at Korys, also joins Commit's Board of Directors Mikkel Wandahl Pedersen appointed as interim CEOView original content:https://www.prnewswire.co.uk/news-releases/commit-biologics-announces-5-5m-seed-financing-extension-investment-by-korys-to-further-develop-its-bispecific-complement-engaging-bice-platform-302361083.html